» Articles » PMID: 16159839

Myocardial Recovery Using Ventricular Assist Devices: Prevalence, Clinical Characteristics, and Outcomes

Overview
Journal Circulation
Date 2005 Sep 15
PMID 16159839
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ventricular assist devices (VADs) are important bridges to cardiac transplantation. VAD support may also function as a bridge to ventricular recovery (BTR); however, clinical predictors of recovery and long-term outcomes remain uncertain. We examined the prevalence, characteristics, and outcomes of BTR subjects in a large single center series.

Methods And Results: We implanted VADs in 154 adults at the University of Pittsburgh from 1996 through 2003. Of these implants, 10 were BTR. This included 2/80 (2.5%) ischemic patients (supported 42 and 61 days, respectively). Both subjects had surgical revascularization, required perioperative left VAD support, and were alive and transplant-free at follow up (232 and 1319 days, respectively). A larger percentage of nonischemic patients underwent BTR (8/74, 11%; age 30+/-14; 88% female; left ventricular ejection fraction 18+/-6%; supported 112+/-76 days). Three had myocarditis, 4 had post-partum cardiomyopathy (PPCM), and 1 had idiopathic cardiomyopathy. Five received biventricular support. After explantation, ventricular function declined in 2 PPCM patients who then required transplantation. Ventricular recovery in the 6 nonischemic patients surviving transplant-free was maintained (left ventricular ejection fraction 54+/-5%; follow-up 1.5+/-0.9 years). Overall, 8 of 10 BTR patients are alive and free of transplant (follow-up 1.6+/-1.1 years).

Conclusions: In a large single center series, BTR was evident in 11% of nonischemic patients, and the need for biventricular support did not preclude recovery. For most BTR subjects presenting with acute inflammatory cardiomyopathy, ventricular recovery was maintained long-term. VAD support as BTR should be considered in the care of acute myocarditis and PPCM.

Citing Articles

Role of Artificial Intelligence and Machine Learning to Create Predictors, Enhance Molecular Understanding, and Implement Purposeful Programs for Myocardial Recovery.

Lang F, Lee B, Lotan D, Sabuncu M, Topkara V Methodist Debakey Cardiovasc J. 2024; 20(4):76-87.

PMID: 39184156 PMC: 11342843. DOI: 10.14797/mdcvj.1392.


Baseline QRS duration associates with cardiac recovery in patients with continuous-flow left ventricular assist device implantation.

Khan M, Kyriakopoulos C, Taleb I, Dranow E, Scott M, Ranjan R Am Heart J Plus. 2024; 22:100211.

PMID: 38558900 PMC: 10978410. DOI: 10.1016/j.ahjo.2022.100211.


Myocardial Recovery.

Chrysakis N, Xanthopoulos A, Magouliotis D, Starling R, Drakos S, Triposkiadis F Diagnostics (Basel). 2023; 13(8).

PMID: 37189604 PMC: 10138096. DOI: 10.3390/diagnostics13081504.


Editorial: Physiology in extreme conditions: Adaptations and unexpected reactions, Volume II.

Trivella M, Capobianco E, LAbbate A Front Physiol. 2023; 14:1181010.

PMID: 36998988 PMC: 10043470. DOI: 10.3389/fphys.2023.1181010.


LVAD as a Bridge to Remission from Advanced Heart Failure: Current Data and Opportunities for Improvement.

Kyriakopoulos C, Kapelios C, Stauder E, Taleb I, Hamouche R, Sideris K J Clin Med. 2022; 11(12).

PMID: 35743611 PMC: 9225013. DOI: 10.3390/jcm11123542.